INDICATION: PONVORY® (ponesimod) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[1]

If you missed Dr Guger’s expert perspective on agile management with PONVORY® at EAN 2022 or simply want to revisit the content, Janssen Neuroscience are pleased to share the recording with you.

Video Not Published

The below topics are covered by Dr Guger during the session:

  • Key attributes of PONVORY®, including key efficacy data from the OPTIMUM study
  • The definition of agile management and when this could be clinically required
  • How PONVORY® provides agility and what the potential benefits of agility are in clinical practice
The slides are
also available
to download


Dr Michael Guger, Neurologist

Oberösterreichische Gesundheitsholding, GmbH Pyhrn-Eisenwurzen Klinikum, Steyr, Austria

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
EAN, European Academy of Neurology; RMS, relapsing multiple sclerosis.